Erratum: Molecular pathways underlying IBD-associated colorectal neoplasia: Therapeutic implications (American Journal of Gastroenterology (2011) 106 (719-730) DOI: 10.1038/ajg.2011.51);Molecular pathways underlying IBD-associated colorectal neoplasia: Therapeutic implications

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 719-730

  Goel, Gati A ^a   Kandiel, Ahmed ^a   Achkar, Jean Paul ^a   Lashner, Bret ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; CANNABINOID; CHEMOKINE RECEPTOR CCR5; CHONDROITIN SULFATE PROTEOGLYCAN 2 PROTEIN; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ETODOLAC; FOLIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MESALAZINE; MYOD PROTEIN; NIMESULIDE; PROBIOTIC AGENT; PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; SECRETED FRIZZLED RELATED PROTEIN 1; SECRETED FRIZZLED RELATED PROTEIN 2; SIMVASTATIN; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE COURSE; DNA DAMAGE; DRUG MECHANISM; EXTRACELLULAR MATRIX; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; INTRACELLULAR SIGNALING; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

EID: 79953799947     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.3     Document Type: Erratum

References (107)

1. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in Infammatory bowel disease. Aliment Pharmacol Ter 2003;18 (Suppl2): 1-5. (Pubitemid 37174709)
2. Winther KV, Jess T, Langholz E et al Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County Clin Gastroenterol Hepatol 2004;2:1088-95. (Pubitemid 40037640)
3. Prior P, Gyde SN, Macartney JC et al Cancer morbidity in ulcerative colitis. Gut 1982;23:490-7. (Pubitemid 12119347)
4. Tekbom A, Helmick C, Zack M et al Ulcerative colitis and colorectal cancer. A population-based study N Engl J Med 1990; 323: 1228-33. (Pubitemid 20366527)
5. Langholz E, Munkholm P Davidsen M et al. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-51.
6. Kewenter J, Ahlman H, Hulten L. Cancer risk in extensive ulcerative colitis. Ann Surg 1978;188:824-8.
7. Teaden J. Review article: colorectal carcinoma and Infammatory bowel disease. Aliment Pharmacol Ter 2004;20 (Suppl4): 24-30.
8. Canavan C, Abrams KR Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ter 2006;23:1097-104. (Pubitemid 43779348)
9. Brackmann S, Andersen SN, Aamodt G et al Two distinct groups of colorec-tal cancer in Infammatory bowel disease. Infamm Bowel Dis 2009; 15: 9-16.
10. Gupta RB, Harpaz N, Itzkowitz S et al Histologic Infammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study Gastroenterology 2007;133:1099-105; quiz 1340-1341.
11. Lutgens MW, Vleggaar FP, Schipper ME et al High frequency of early colorectal cancer in Infammatory bowel disease. Gut 2008; 57: 1246-51.
12. Rutter MD, Saunders BP, Wilkinson KH et al Tirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030-8.
13. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
14. Yoshizawa S, Matsuoka K, Inoue N et al Clinical signif cance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis. Infamm Bowel Dis 2007;13:865-73. (Pubitemid 47203864)
15. Itzkowitz SH. Molecular biology of dysplasia and cancer in Infammatory bowel disease. Gastroenterol Clin North Am 2006;35:553-71. (Pubitemid 44307575)
16. Dhir M, Montgomery EA, Glockner SC et al Epigenetic regulation of WNT signaling pathway genes in Infammatory bowel disease (IBD) associated neoplasia. J Gastrointest Surg 2008;12:1745-53.
17. Umetani N, Sasaki S, Watanabe Tet al Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability. Jpn J Cancer Res 1999;90:1081-7.
18. Tahara T, Inoue N, Hisamatsu Tet al. Clinical signif cance of microsatellite instability in the inf amed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J Gastroenterol Hepatol 2005;20:710-5. (Pubitemid 40733364)
19. Fujiwara I, Yashiro M, Kubo N et al. Ulcerative colitis-associated colorectal cancer is frequently associated with the microsatellite instability pathway Dis Colon Rectum 2008; 51: 1387-94.
20. Issa JP, Ahuja N, Toyota M et al Accelerated age-related CpG island meth-ylation in ulcerative colitis. Cancer Res 2001; 61: 3573-7. (Pubitemid 32694963)
21. Leedham SJ, GrahamTA, OukrifD et al. Clonality foundermutations, and f eld cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology 2009;136:542-550.e6.
22. Cartwright CA, Coad CA, Egbert BM. Elevated c-Src tyrosine kinase activity in premalignanTepithelia of ulcerative colitis. J Clin Invest 1994; 93: 509-15. (Pubitemid 24072789)
23. Kukitsu T Takayama T, Miyanishi K et al. Aberrant crypt foci as precursors of the dysplasia-carcinoma sequence in patients with ulcerative colitis. Clin Cancer Res 2008;14:48-54. (Pubitemid 351377977)
24. Li W Khor TO, Xu C et al Activation of Nrf2-antioxidant signaling at-tenuates NFkappaB-Infammatory response and elicits apoptosis. Biochem Pharmacol 2008; 76: 1485-9.
25. Liao J, Seril DN, Lu GG et al Increased susceptibility of chronic ulcera-tive colitis-induced carcinoma development in DNA repair enzyme Ogg1 defcient mice. Mol Carcinog 2008;47:638-46.
26. Liao J, Seril DN, Yang AL et al Inhibition of chronic ulcerative colitis associated adenocarcinoma development in mice by inositol compounds. Carcinogenesis 2007; 28: 446-54. (Pubitemid 46321862)
27. Teberhart CE, Cofey RJ, Radhika A et al Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8. (Pubitemid 24294584)
28. Liu ZG. Molecular mechanism of TNF signaling and beyond. Cell Res 2005;15:24-7.
29. Kitakata H, Nemoto-Sasaki Y Takahashi Y et al Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administra-tion of colon 26 cells. Cancer Res 2002;62:6682-7. (Pubitemid 35364138)
30. Tomita Y Yang X, Ishida Y et al Spontaneous regression of lung metas-tasis in the absence of tumor necrosis factor receptor p55. Int J Cancer 2004;112:927-33. (Pubitemid 39506997)
31. Liu R, Bal HS, Desta Tet al. Tumor necrosis factor-alpha mediates dia-betes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol 2006;168:757-64. (Pubitemid 43327728)
32. Popivanova BK, Kitamura K, Wu Y et al Blocking TNF-alpha in mice re-duces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 2008;118:560-70. (Pubitemid 351206546)
33. Yan B, Wang H Rabbani ZN et al Tumor necrosis factor-alpha is a potenTendogenous mutagen that promotes cellular transformation. Cancer Res 2006;66:11565-70. (Pubitemid 46094163)
34. Li Q, Withof S, Verma IM. Infammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 2005; 26: 318-25.
35. Greten F R, Eckmann L, Greten TF et al IKKbeta links Infammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-96. (Pubitemid 39061110)
36. Hanai H, Sugimoto K. Curcumin has bright prospects for the treatment of infammatorybowel disease. Curr Pharm Des 2009;15:2087-94.
37. Park J, Conteas CN. Anti-carcinogenic properties of curcumin on colorec-tal cancer. World J Gastrointest Oncol 2010;2:169-76.
38. Reddy S, Rishi AK, Xu H et al Mechanisms of curcumin-and EGF-recep-tor related protein (ERRP)-dependent growth inhibition of colon cancer cells. Nutr Cancer 2006;55:185-94. (Pubitemid 44719633)
39. Choo MK Sakurai H, Kim DH et al A ginseng saponin metabolite sup-presses tumor necrosis factor-alpha-promoted metastasis by suppressing nuclear factor-kappaB signaling in murine colon cancer cells. Oncol Rep 2008;19:595-600. (Pubitemid 351330423)
40. Zhang M, Deng C, Zheng J et al Curcumin inhibits trinitrobenzene sul-phonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int Immunopharmacol 2006;6:1233-42. (Pubitemid 43868183)
41. Becker C, Fantini MC, Schramm C et al TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21:491-501. (Pubitemid 39370505)
42. Li Y de Haar C, Chen M et al Disease-related expression of the IL-6/STAT3/SOCS3 signaling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut 2010;59:227-35.
43. Singer II, Kawka DW, Schloemann S et al Cyclooxygenase 2 is induced in colonic epithelial cells in Infammatory bowel disease. Gastroenterology 1998;115:297-306. (Pubitemid 28363422)
44. Shattuck-Brandt RL, Varilek GW, Radhika A et al Cyclooxygenase 2 ex-pression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 2000;118:337-45. (Pubitemid 30067507)
45. Zhang R, Ma A, Urbanski SJ et al Induction of inducible nitric oxide synthase: a protective mechanism in colitis-induced adenocarcinoma. Carcinogenesis 2007;28:1122-30. (Pubitemid 47072200)
46. Beatty PL, Plevy SE, Sepulveda AR et al Cutting edge: transgenic expres-sion of human MUC1 in IL-10-/-mice accelerates Infammatory bowel disease and progression to colon cancer. J Immunol 2007;179:735-9.
47. Wendt MK, Johanesen PA, Kang-Decker N et al. Silencing ofepithelial CXCL12 expression by DNA hypermethylation promotes colonic carci-noma metastasis. Oncogene 2006; 25: 4986-97.
48. Andres PG, Beck PL, Mizoguchi E et al Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1+ lymphocyte-associated T 2-type immune response in the intestine. J Immunol 2000;164:6303-12. (Pubitemid 30408811)
49. Popivanova BK, Kostadinova FI, Furuichi K et al Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 2009; 69: 7884-92.
50. Yarbro CH, Wujcik D, Tomas M et al EGFR-targeted therapy for patients with colorectal cancer: patient management and future directions. ONS News 2004;19:53-4.
51. Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy Clin Colorectal Cancer 2005;5 (Suppl1): S19-27.
52. Viret F, Goncalves A. [Metastatic colorectal cancers and targeted therapy againsTeGFR]. Med Sci (Paris) 2009;25 (Spec No 1): 13-21.
53. Zampino MG, Magni E, Massacesi C et al First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplif ed FOLFOX6 as f rst-line treatment for metastatic colorectal cancer. Cancer 2007;110:752-8. (Pubitemid 47257650)
54. Alexander RJ, Panja A, Kaplan-Liss E et al Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in Infamma-torybowel disease. Dig Dis Sci 1995;40:485-94.
55. Hernandez Y, Sotolongo J, Breglio K et al Te role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neopla-sia. BMC Gastroenterol 2010;10:82.
56. Hahm KB, Im YH, Parks TW et al Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in Infammatory bowel disease. Gut 2001;49:190-8. (Pubitemid 32675110)
57. Souza RF, Garrigue-Antar L, Lei J et al Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcino-mas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms. Hum Cell 1996; 9: 229-36.
58. Sturlan S, Oberhuber G, Beinhauer BG et al Interleukin-10-def cient mice and Infammatory bowel disease associated cancer development. Carcino-genesis 2001;22:665-71. (Pubitemid 32288669)
59. Hachimine D, Uchida K, Asada M et al Involvement of Smad3 phosphoi-soform-mediated signaling in the development of colonic cancer in IL-10-defcient mice. Int J Oncol 2008;32:1221-6.
60. Tengle SJ, Ormsby I, Pawlowski et al. Elimination of colon cancer in germ-free transforming growth factor beta 1-defcient mice. Cancer Res 2002;62:6362-6.
61. Nowak J, Weylandt KH, HabbelP et al Colitis-associated colon tumori-genesis is suppressed in transgenic mice rich in endogenous n-3 fatty acids. Carcinogenesis 2007;28:1991-5. (Pubitemid 47500613)
62. Wada K, Tanaka H, Maeda K et al Vitamin D receptor expression is associ-ated with colon cancer in ulcerative colitis. Oncol Rep 2009;22:1021-5.
63. Fichera A, Little N, Dougherty U et al A vitamin D analogue inhibits colonic carcinogenesis in the AOM/DSS model. J Surg Res 2007; 142: 239-45. (Pubitemid 47418822)
64. Kado S, Uchida K, Funabashi H et al. Intestinal microf ora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res 2001;61:2395-8. (Pubitemid 32685812)
65. Balish E, Warner Tenterococcus faecalis induces Infammatory bowel disease in interleukin-10 knockout mice. Am J Pathol 2002;160:2253-7. (Pubitemid 34663415)
66. Chu FF, Esworthy RS, Chu PG et al Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes. Cancer Res 2004;64:962-8. (Pubitemid 38176898)
67. Chen GY, Shaw MH, Redondo G et al Te innate immune receptor Nod1 protects the intestine from infammation-induced tumorigenesis. Cancer Res 2008; 68: 10060-7.
68. Fukata M, Chen A, Vamadevan AS et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133:1869-81.
69. Uronis JM, Muhlbauer M, Herfarth HH et al Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility PLoS One 2009;4:e6026.
70. Jia Q, Lupton JR, Smith R et al Reduced colitis-associated colon cancer in Fat-1 (n-3 fatty aciddesaturase) transgenic mice. Cancer Res 2008;68:3985-91.
71. Matsumoto S, Hara T, Nagaoka M et al. A component of polysaccharide peptidoglycan complex on Lactobacillus induced an improvement of murine model of Infammatory bowel disease and colitis-associated cancer. Immunology 2009;128:e170-80.
72. Manfredi MA, Zurakowski D, Rufo PA et al. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with Infammatory bowel disease. Infamm Bowel Dis 2008;14:1091-6.
73. Garg P, Vijay-Kumar M, Wang L et al Matrix metalloproteinase-9-mediat-ed tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G175-84.
74. Garg P, arma D, Jeppsson S et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res 2010;70:792-801.
75. Rath T, Roderfeld M, Graf J et al Enhanced expression of MMP-7 and MMP-13 in Infammatory bowel disease: a precancerous potential? In-famm Bowel Dis 2006;12:1025-35. (Pubitemid 44665472)
76. Kawabata K, Murakami A, Ohigashi H. Auraptene decreases the activity of matrix metalloproteinases in dextran sulfate sodium-induced ulcerative colitis in ICR mice. Biosci Biotechnol Biochem 2006; 70: 3062-5. (Pubitemid 46021571)
77. Assi K, Mil ls J, Owen D et al. Integrin-linked kinase regulates cell proliferation and tumour growth in murine colitis-associated carcinogenesis. Gut 2008;57:931-40. (Pubitemid 351919528)
78. Boolbol SK, Dannenberg AJ, Chadburn A et al Cyclooxygenase-2 overex-pression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556-60. (Pubitemid 26171681)
79. Sun BC, Zhao XL, Zhang SW et al Sulindac induces apoptosis and protects against colon carcinoma in mice. World J Gastroenterol 2005;11:2822-6.
80. Taketo MM. COX-2 and colon cancer. Infamm Res 1998; 47 (Suppl 2): S112-6. (Pubitemid 28493278)
81. Taylor MT, Lawson KR, Ignatenko NA et al Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells. Cancer Res 2000;60:6607-10.
82. Xiao D, Deguchi A, Gundersen GG et al Te sulindac derivatives OSI-461, OSIP486823, and OSIP487703 arrest colon cancer cells in mitosis by caus-ing microtubule depolymerization. Mol Cancer Ter 2006;5:60-7.
83. Mladenova D, Daniel JJ, Dahlstrom JE et al Te NSAID sulindac is che-mopreventive in the mouse distal colon but carcinogenic in the proximal colon. Gut 2011;60:350-60.
84. Hu Y Le Leu RK, Young GP. Sulindac corrects defective apoptosis and sup-presses azoxymethane-induced colonic oncogenesis in p53 knockout mice. Int J Cancer 2005;116:870-5. (Pubitemid 41209192)
85. Pangburn HA, Kraus H, Ahnen DJ et al Sulindac metabolites inhibiTepidermal growth factor receptor activation and expression. J Carcinog 2005;4:16.
86. Inoue T, Hirata I, Murano M. Effects of nimesulide, a cyclooxygenase-2 selective inhibitor, on colitis induced tumors. Infammopharmacology 2008;16:36-9. (Pubitemid 351225997)
87. Mukawa K, Fujii S, Tominaga K et al Inhibitory Effects of the cyclooxygen-ase-2 inhibitor, etodolac, on colitis-associated tumorigenesis in p53-def-cient mice treated with dextran sulfate sodium. Oncol Rep 2008; 19: 393-9. (Pubitemid 351176099)
88. Takeda J, Kitajima K, Fujii S et al Inhibitory Effects of etodolac, a selective COX-2 inhibitor, on the occurrence of tumors in colitis-induced tumori-genesis model in rats. Oncol Rep 2004; 11: 981-5.
89. Li Y Niu Y Wu H et al PC-407, a celecoxib derivative, inhibited the growth ofcolorectal tumor in vitro and in vivo. Cancer Sci 2009;100:2451-8.
90. Chu EC, Chai J, Ahluwalia A et al. Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? Aliment Pharmacol Ter 2007;25:1443-9. (Pubitemid 46848890)
91. Brown JB, Lee G, Managlia E et al Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology 2010;138:595-605, 605.e1-3.
92. Koelink PJ, Robanus-Maandag EC, Devilee P et al 5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model. Carcinogenesis 2009;30:1217-24.
93. Das KK, Bajpai M, Kong Y et al Mesalamine suppresses the expression of TC22, a novel tropomyosin isoform associated with colonic neoplasia. Mol Pharmacol 2009; 76: 183-91.
94. Velayos FS, Terdiman JP, Walsh JM. effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis ofobservational studies. Am J Gastroenterol 2005;100:1345-53. (Pubitemid 40904360)
95. Bernstein CN, Eaden J, Steinhart AH et al Cancer prevention in Infammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Infamm Bowel Dis 2002;8:356-61.
96. Teaden J, Abrams K, Ekbom A et al Colorectal cancer prevention in ulcerative colitis: a case-control study Aliment Pharmacol Ter 2000; 14: 145-53. (Pubitemid 30088290)
97. Ullman T, Croog V, Harpaz N et al Progression to colorectal neoplasia in ulcerative colitis: efect of mesalamine. Clin Gastroenterol Hepatol 2008. 6:1225-30; quiz 1177.
98. Phelip JM, Ducros V, Faucheron JL et al. Association of hyperhomo-cysteinemia and folate def ciency with colon tumors in patients with infammatorybowel disease. Infamm Bowel Dis 2008;14:242-8. (Pubitemid 351288046)
99. Chapkin RS, Kamen BA, Callaway ES et al Use of a novel genetic mouse model to investigate the role of folate in colitis-associated colon cancer. J Nutr Biochem 2009;20:649-55.
100. Lashner BA, Provencher KS, Seidner DL et al. Te effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32. (Pubitemid 27008982)
101. Shah SA, Looby E, Volkov Y et al. Ursodeoxycholic acid inhibits transloca-tion of protein kinase C in human colonic cancer cell lines. Eur J Cancer 2005;41:2160-9. (Pubitemid 41337959)
102. Kohno H, Suzuki R, Yasui Y et al Ursodeoxycholic acid versus sulfasala-zine in colitis-related colon carcinogenesis in mice. Clin Cancer Res 2007;13:2519-25. (Pubitemid 46698605)
103. Pardi DS, Lofus EV Jr, Kremers WK et al Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93. (Pubitemid 36389790)
104. D Argenio G, Valenti M, Scaglione G et al Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon infammation. FASEB J 2006;20:568-70. (Pubitemid 46671252)
105. Pele LC, Toree V, Mustafa F et al Low dietary calcium levels modulate mucosal caspase expression and increase disease activity in mice with dextran sulfate sodium induced colitis. J Nutr 2007;137:2475-80. (Pubitemid 350058719)
106. Lee JY, Kim JS, Kim JM et al Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Im-munopharmacol 2007; 7: 241-8. (Pubitemid 46037564)
107. Kanagarajan N, Nam JH, Noah ZA et al Disease modifying effect of statins in dextran sulfate sodium model of mouse colitis. Infamm Res 2008;57:34-8.